

12^a
ACTUALIZACIÓN
en el TRATAMIENTO
LEUCEMIA
AGUDA 2023



del 5 al 7
OCT
2023

Dr David Valcarcel

*Institute of Oncology, Hospital Quirónsalud
Barcelona, Spain*

David Valcárcel Ferreiras graduated in Medicine and Surgery from the University of Valencia in 1998 and specialized in Hematology and Hemotherapy at the Hospital de la Santa Creu i Sant Pau between 1999 and 2003. In 2014, he obtained his PhD degree with a thesis on the role of reduced-intensity conditioning allogeneic transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia. Since 2013, he has been an associate professor at the Universitat Autònoma de Barcelona.

His career has developed in both clinical and research fields, working as an assistant physician at the Hospital de la Santa Creu i Sant Pau from 2004 to 2006, and again from 2006 to 2010, after a brief period at the Hospital Clínico de Valencia. Since 2010, he has been directing the Transplantation and Cellular Therapy Unit at the Hospital Vall d'Hebron, serving as head of the section since 2017.

Dr. Valcárcel has extensive experience in various neoplastic and non-neoplastic diseases, especially myelodysplastic syndromes, allogeneic hematopoietic progenitor cell transplantation, and immune thrombocytopenia. He has participated in numerous phase I-IV clinical trials.

He has published more than 150 scientific articles in international journals, including the Journal of Clinical Oncology, Blood, Lancet Haematology, and Leukemia, among others. He has also collaborated on various clinical guidelines and book chapters. Currently, he directs the Myeloid Pathology Research Group in the Experimental Hematology Group at the Vall Hebron Institute of Oncology-Hospital Vall d'Hebron.

He is a member of several scientific societies, including the Spanish Society of Hematology and Hemotherapy (ESHH), the European Haematology Association (EHA), the European Society Blood and Marrow Transplant (EBMT) the American Society of Haematology (ASH) and the American Society for Blood and the Marrow Transplantation (ASBMT). Additionally, he is the vice president of the Spanish Group of Myelodysplastic Syndrome (GESMD), coordinates the regulatory and accreditation group of the Spanish Group of Transplantation and Cellular Therapy (GETH-CT), and is part of the board of directors of the Spanish Group of Immune Thrombocytopenia (GEPTI).